Rhythm Pharmaceuticals, Inc. (RYTM) fundamentals score
Rhythm Pharmaceuticals is a global, commercial-stage biopharmaceutical company dedicated to transforming the lives of patients living with rare neuroendocrine diseases. It is focused on advancing melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as precision medicines designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases.
Pharmaceutical Preparations · Healthcare · Listed on NASDAQ
Overall: 5.4 out of 10, Mixed fundamentals
- Growth: 4.5/10
- Profitability: 4.0/10
- Financial health: 6.8/10
- Earnings quality: 7.0/10
- Valuation: 5.5/10
Scores are calculated from Rhythm Pharmaceuticals, Inc.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10